{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:53:49Z","timestamp":1790715229239,"version":"4.1.0"},"reference-count":128,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":393,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jacc.2024.05.084","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T10:03:44Z","timestamp":1729505024000},"page":"1748-1766","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Aspirin Hypersensitivity in Patients With Atherosclerotic Cardiovascular Disease"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3909-182X","authenticated-orcid":false,"given":"Mattia","family":"Galli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Cortellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0157-7242","authenticated-orcid":false,"given":"Giovanni","family":"Occhipinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7298-2037","authenticated-orcid":false,"given":"Roberta","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2024.05.084_bib1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/bmj.1.803.627","article-title":"The treatment of rheumatism by salicin and salicylic acid","volume":"1","author":"Maclagan","year":"1876","journal-title":"Br Med J"},{"key":"10.1016\/j.jacc.2024.05.084_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3406\/pharm.2007.6334","article-title":"[From the willow to aspirin]","volume":"55","author":"Lafont","year":"2007","journal-title":"Rev Hist Pharm (Paris)"},{"key":"10.1016\/j.jacc.2024.05.084_bib3","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1056\/NEJM197905173002006","article-title":"Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls","volume":"300","author":"Moncada","year":"1979","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.084_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI27291","article-title":"Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities","volume":"116","author":"Grosser","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2024.05.084_bib5","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1182\/blood-2006-01-010645","article-title":"Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions","volume":"109","author":"Undas","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2024.05.084_bib6","first-page":"179","article-title":"The discovery of aspirin's antithrombotic effects","volume":"34","author":"Miner","year":"2007","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.jacc.2024.05.084_bib7","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","volume":"2","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.05.084_bib8","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41569-019-0225-y","article-title":"Role of aspirin in primary prevention of cardiovascular disease","volume":"16","author":"Patrono","year":"2019","journal-title":"Nat Rev Cardio"},{"key":"10.1016\/j.jacc.2024.05.084_bib9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrd2957","article-title":"Antiplatelet therapies for the treatment of cardiovascular disease","volume":"9","author":"Michelson","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jacc.2024.05.084_bib10","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.05.084_bib11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ehjcvp\/pvae008","article-title":"Aspirin hypersensitivity and intolerance","volume":"10","author":"Galli","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2024.05.084_bib12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000358618","article-title":"Aspirin hypersensitivity","volume":"100","author":"Sanchez-Borges","year":"2014","journal-title":"Chem Immunol Allergy"},{"key":"10.1016\/j.jacc.2024.05.084_bib13","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/all.12260","article-title":"Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs","volume":"68","author":"Kowalski","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jacc.2024.05.084_bib14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaci.2015.06.021","article-title":"Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug-related urticaria and angioedema","volume":"136","author":"Kowalski","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jacc.2024.05.084_bib15","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"Prostaglandins and inflammation","volume":"31","author":"Ricciotti","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2024.05.084_bib16","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jaci.2003.12.323","article-title":"Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma","volume":"113","author":"Mastalerz","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jacc.2024.05.084_bib17","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/01.STR.23.10.1400","article-title":"Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin","volume":"23","author":"Tohgi","year":"1992","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2024.05.084_bib18","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.084_bib19","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJMcibr1514013","article-title":"Aspirin-exacerbated respiratory disease--new prime suspects","volume":"374","author":"Laidlaw","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.084_bib20","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.4049\/jimmunol.168.11.5811","article-title":"Lipopolysaccharide-dependent prostaglandin E(2) production is regulated by the glutathione-dependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4\/MyD88\/NF-IL6 pathway","volume":"168","author":"Uematsu","year":"2002","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jacc.2024.05.084_bib21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/01.fpc.0000239977.61841.fe","article-title":"Association between polymorphisms in prostanoid receptor genes and aspirin-intolerant asthma","volume":"17","author":"Kim","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jacc.2024.05.084_bib22","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jaci.2019.08.022","article-title":"Aspirin sensitivity: Lessons in the regulation (and dysregulation) of mast cell function","volume":"144","author":"Boyce","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jacc.2024.05.084_bib23","first-page":"45","article-title":"Aspirin exacerbated respiratory disease: epidemiology, pathophysiology, and management","volume":"7","author":"Li","year":"2019","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.jacc.2024.05.084_bib24","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2222.2006.02498.x","article-title":"Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis","volume":"36","author":"Peters-Golden","year":"2006","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jacc.2024.05.084_bib25","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.3390\/ijms20143580","article-title":"The role of leukotrienes as potential therapeutic targets in allergic disorders","volume":"20","author":"Jo-Watanabe","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2024.05.084_bib26","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/S0954-6111(11)70017-8","article-title":"Acetylsalicylic acid-triggered 15-HETE generation by peripheral leukocytes for identifying ASA sensitivity","volume":"105","author":"Korosec","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.jacc.2024.05.084_bib27","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jaci.2015.10.020","article-title":"Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Buchheit","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jacc.2024.05.084_bib28","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/j.1398-9995.2005.00836.x","article-title":"Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest)","volume":"60","author":"Kowalski","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jacc.2024.05.084_bib29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3904\/kjim.2011.26.1.8","article-title":"Prostaglandin D(2) and T(H)2 inflammation in the pathogenesis of bronchial asthma","volume":"26","author":"Arima","year":"2011","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jacc.2024.05.084_bib30","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jaci.2016.04.042","article-title":"Eosinophil production of prostaglandin D(2) in patients with aspirin-exacerbated respiratory disease","volume":"138","author":"Feng","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jacc.2024.05.084_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaci.2014.07.031","article-title":"Prostaglandin D(2): a dominant mediator of aspirin-exacerbated respiratory disease","volume":"135","author":"Cahill","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jacc.2024.05.084_bib32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1146\/annurev.pathmechdis.3.121806.151409","article-title":"Anti-inflammatory and proresolving lipid mediators","volume":"3","author":"Serhan","year":"2008","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jacc.2024.05.084_bib33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1034\/j.1399-3003.2000.16a08.x","article-title":"Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics","volume":"16","author":"Sanak","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2024.05.084_bib34","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1111\/j.1398-9995.2009.02047.x","article-title":"Lipoxin A4 generation is decreased in aspirin-sensitive patients in lysine-aspirin nasal challenge in\u00a0vivo model","volume":"64","author":"Kupczyk","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jacc.2024.05.084_bib35","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.iac.2016.06.010","article-title":"Genetic and epigenetic components of aspirin-exacerbated respiratory disease","volume":"36","author":"Dahlin","year":"2016","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jacc.2024.05.084_bib36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jaip.2016.10.021","article-title":"Current knowledge and management of hypersensitivity to aspirin and NSAIDs","volume":"5","author":"Laidlaw","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacc.2024.05.084_bib37","first-page":"363","article-title":"Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients","volume":"22","author":"Dona","year":"2012","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jacc.2024.05.084_bib38","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.anai.2016.12.020","article-title":"Allergy entry and deletion in the electronic health record","volume":"118","author":"Blumenthal","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacc.2024.05.084_bib39","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/bmj.328.7437.434","article-title":"Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice","volume":"328","author":"Jenkins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2024.05.084_bib40","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2014.08.020","article-title":"Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature","volume":"135","author":"Rajan","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jacc.2024.05.084_bib41","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/ije\/28.4.717","article-title":"Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study","volume":"28","author":"Hedman","year":"1999","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jacc.2024.05.084_bib42","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40119-022-00255-9","article-title":"Coronary artery disease and aspirin intolerance: background and insights on current management","volume":"11","author":"Thakker","year":"2022","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.jacc.2024.05.084_bib43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ahj.2018.06.011","article-title":"Aspirin hypersensitivity in patients with coronary artery disease: linking pathophysiology to clinical practice","volume":"203","author":"Gnanenthiran","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2024.05.084_bib44","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.anai.2012.11.013","article-title":"Characterization of aspirin allergies in patients with coronary artery disease","volume":"110","author":"Feng","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacc.2024.05.084_bib45","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jaip.2020.08.006","article-title":"Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs","volume":"8","author":"Broyles","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacc.2024.05.084_bib46","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jaci.2022.08.028","article-title":"Drug allergy: a 2022 practice parameter update","volume":"150","author":"Khan","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jacc.2024.05.084_bib47","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1398-9995.2011.02557.x","article-title":"Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI\/ENDA(#) and GA2LEN\/HANNA\u2217","volume":"66","author":"Kowalski","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jacc.2024.05.084_bib48","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.jaip.2023.03.036","article-title":"Evaluation and updated classification of acute hypersensitivity reactions to nonsteroidal anti-inflammatory drugs (NSAIDs): NSAID-exacerbated or -induced food allergy","volume":"11","author":"Romano","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacc.2024.05.084_bib49","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1365-2222.2005.2228.x","article-title":"Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs","volume":"35","author":"Asero","year":"2005","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jacc.2024.05.084_bib50","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000342424","article-title":"Clinical management of patients with a history of urticaria\/angioedema induced by multiple NSAIDs: an expert panel review","volume":"160","author":"Asero","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jacc.2024.05.084_bib51","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1067\/mai.2000.104571","article-title":"Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema","volume":"105","author":"Wong","year":"2000","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jacc.2024.05.084_bib52","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ijcard.2012.01.063","article-title":"Aspirin desensitization in patients undergoing planned or urgent coronary stent implantation. A single-center experience","volume":"167","author":"De Luca","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2024.05.084_bib53","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jaci.2006.06.019","article-title":"Selection of patients for aspirin desensitization treatment","volume":"118","author":"Stevenson","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jacc.2024.05.084_bib54","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/0091-6749(80)90143-8","article-title":"Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges","volume":"66","author":"Stevenson","year":"1980","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jacc.2024.05.084_bib55","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/ACI.0b013e3280108716","article-title":"Desensitization for drug allergy","volume":"6","author":"Castells","year":"2006","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jacc.2024.05.084_bib56","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.amjcard.2007.10.045","article-title":"Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation","volume":"101","author":"Rossini","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.05.084_bib57","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/all.13068","article-title":"Clinical approach on challenge and desensitization procedures with aspirin in patients with ischemic heart disease and nonsteroidal anti-inflammatory drug hypersensitivity","volume":"72","author":"Cortellini","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jacc.2024.05.084_bib58","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.iac.2012.11.003","article-title":"Mechanisms of aspirin desensitization","volume":"33","author":"Burnett","year":"2013","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jacc.2024.05.084_bib59","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.iac.2016.06.011","article-title":"Mechanisms of benefit with aspirin therapy in aspirin-exacerbated respiratory disease","volume":"36","author":"Hill","year":"2016","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jacc.2024.05.084_bib60","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.amjcard.2004.10.022","article-title":"Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting","volume":"95","author":"Silberman","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.05.084_bib61","first-page":"87","article-title":"Rapid oral aspirin desensitization for patients with aspirin allergy requiring dual antiplatelet therapy","volume":"72","author":"Hobbs","year":"2008","journal-title":"Conn Med"},{"key":"10.1016\/j.jacc.2024.05.084_bib62","first-page":"307","article-title":"Rapid desensitisation of patients with aspirin allergy who undergo coronary angioplasty","volume":"52","author":"Christou","year":"2011","journal-title":"Hellenic J Cardiol"},{"key":"10.1016\/j.jacc.2024.05.084_bib63","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/ACI.0000000000000374","article-title":"Aspirin challenge and desensitization: how, when and why","volume":"17","author":"Cortellini","year":"2017","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jacc.2024.05.084_bib64","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjcard.2019.03.047","article-title":"Meta-analysis of acetylsalicylic acid desensitization in patients with acute coronary syndrome","volume":"124","author":"Chopra","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.05.084_bib65","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.002896","article-title":"Efficacy and safety of available protocols for aspirin hypersensitivity for patients undergoing percutaneous coronary intervention: a survey and systematic review","volume":"9","author":"Bianco","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.05.084_bib66","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.116.004368","article-title":"Aspirin desensitization in patients with coronary artery disease: results of the multicenter ADAPTED registry (Aspirin Desensitization in Patients With Coronary Artery Disease)","volume":"10","author":"Rossini","year":"2017","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.05.084_bib67","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s11239-023-02782-1","article-title":"Acetylsalicylic acid challenge or desensitization in sensitive patients with cardiovascular disease","volume":"55","author":"Cortellini","year":"2023","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jacc.2024.05.084_bib68","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcin.2020.01.226","article-title":"derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score","volume":"13","author":"Angiolillo","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.05.084_bib69","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.05.084_bib70","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/jama.2022.5207","article-title":"Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force Recommendation Statement","volume":"327","author":"Davidson","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2024.05.084_bib71","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.084_bib72","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jacc.2022.11.041","article-title":"P2Y(12) inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions","volume":"81","author":"Gragnano","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.084_bib73","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.05.084_bib74","doi-asserted-by":"crossref","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","article-title":"Antiplatelet therapy after percutaneous coronary intervention","volume":"17","author":"Angiolillo","year":"2022","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jacc.2024.05.084_bib75","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1016\/j.jacc.2021.07.053","article-title":"2021 AHA\/ACC\/ASE\/CHEST\/SAEM\/SCCT\/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"78","author":"Gulati","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.084_bib76","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.05.084_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcin.2022.10.023","article-title":"Timing, selection, modulation, and duration of P2Y(12) inhibitors for patients with acute coronary syndromes undergoing PCI","volume":"16","author":"Capodanno","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.05.084_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.975969","article-title":"De-escalation of antiplatelet therapy in acute coronary syndromes: why, how and when?","volume":"9","author":"Galli","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2024.05.084_bib79","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41569-018-0049-1","article-title":"Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention","volume":"15","author":"Capodanno","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2024.05.084_bib80","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14740338.2021.1850691","article-title":"Safety and efficacy of P2Y(12) inhibitor monotherapy in patients undergoing percutaneous coronary interventions","volume":"20","author":"Galli","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jacc.2024.05.084_bib81","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A\u00a0randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","author":"Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.05.084_bib82","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.05.084_bib83","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2Y(12) inhibitor or aspirin monotherapy for secondary prevention of coronary events","volume":"82","author":"Gragnano","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.084_bib84","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/ehjcvp\/pvad085","article-title":"Impact of ethnicity on antiplatelet treatment regimens for bleeding reduction in acute coronary syndromes: a systematic review and pre-specified subgroup meta-analysis","volume":"10","author":"Galli","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2024.05.084_bib85","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.05.084_bib86","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.05.084_bib87","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/eurheartj\/ehab836","article-title":"Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials","volume":"43","author":"Galli","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.05.084_bib88","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2217\/pgs-2022-0057","article-title":"Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention","volume":"23","author":"Galli","year":"2022","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jacc.2024.05.084_bib89","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tcm.2021.12.007","article-title":"Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention","volume":"33","author":"Galli","year":"2023","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.jacc.2024.05.084_bib90","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jcin.2020.06.023","article-title":"Aspirin-free prasugrel monotherapy following coronary artery stenting in patients with stable CAD: the ASET pilot study","volume":"13","author":"Kogame","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.05.084_bib91","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.123.066720","article-title":"An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial","volume":"149","author":"Natsuaki","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.05.084_bib92","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.biopha.2016.09.057","article-title":"Potential blood clotting factors and anticoagulants","volume":"84","author":"Jin","year":"2016","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jacc.2024.05.084_bib93","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2165\/00003495-199244030-00009","article-title":"Indobufen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cerebral, peripheral and coronary vascular disease","volume":"44","author":"Wiseman","year":"1992","journal-title":"Drugs"},{"key":"10.1016\/j.jacc.2024.05.084_bib94","first-page":"105","article-title":"Comparison of aspirin and indobufen in healthy volunteers","volume":"27","author":"Lee","year":"2016","journal-title":"Platelets"},{"key":"10.1016\/j.jacc.2024.05.084_bib95","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1055\/s-0038-1648422","article-title":"The d-enantiomer form of indobufen totally accounts for the anti-cyclooxygenase and antiplatelet activity ex\u00a0vivo and for the increase in bleeding time by indobufen in man","volume":"67","author":"De Caterina","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2024.05.084_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.950719","article-title":"Effect of indobufen vs. aspirin on platelet accumulation in patients with stable coronary heart disease after percutaneous coronary intervention: an open-label crossover study","volume":"13","author":"Shi","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacc.2024.05.084_bib97","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/09537104.2012.686072","article-title":"Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention","volume":"24","author":"Barilla","year":"2013","journal-title":"Platelets"},{"key":"10.1016\/j.jacc.2024.05.084_bib98","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ijcard.2011.08.080","article-title":"Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: a proposed alternative regimen","volume":"165","author":"Latib","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2024.05.084_bib99","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1161\/CIRCULATIONAHA.122.062762","article-title":"Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): a randomized, open-label, end point-blinded, noninferiority trial","volume":"147","author":"Wu","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.05.084_bib100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1161\/01.ATV.3.4.383","article-title":"Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin","volume":"3","author":"Rao","year":"1983","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.jacc.2024.05.084_bib101","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2125.1991.tb05500.x","article-title":"Effect of racemic ibuprofen dose on the magnitude and duration of platelet cyclo-oxygenase inhibition: relationship between inhibition of thromboxane production and the plasma unbound concentration of S(+)-ibuprofen","volume":"31","author":"Evans","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2024.05.084_bib102","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Bhala","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.05.084_bib103","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17512433.2023.2154651","article-title":"Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications","volume":"16","author":"Galli","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jacc.2024.05.084_bib104","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/ehjcvp\/pvab043","article-title":"Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials","volume":"8","author":"Galli","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2024.05.084_bib105","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1055\/a-1730-8725","article-title":"Pharmacodynamic profiles of dual-pathway inhibition with or without clopidogrel versus dual antiplatelet therapy in patients with atherosclerotic disease","volume":"122","author":"Galli","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2024.05.084_bib106","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ehjcvp\/pvac022","article-title":"Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy","volume":"8","author":"Galli","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2024.05.084_bib107","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1055\/a-2098-6639","article-title":"Switching from dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor to dual pathway inhibition with aspirin plus vascular-dose rivaroxaban: the Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study","volume":"124","author":"Ortega-Paz","year":"2024","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2024.05.084_bib108","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(17)30751-1","article-title":"Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial","volume":"389","author":"Ohman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.05.084_bib109","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1600-0404.1999.tb00658.x","article-title":"Second European Stroke Prevention Study: antiplatelet therapy is effective regardless of age. ESPS2 Working Group","volume":"99","author":"Sivenius","year":"1999","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jacc.2024.05.084_bib110","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1001\/jama.2009.623","article-title":"Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials","volume":"301","author":"Berger","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2024.05.084_bib111","first-page":"CD000535","article-title":"Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery","volume":"2015","author":"Bedenis","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2024.05.084_bib112","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2014-000068","article-title":"Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials","volume":"1","author":"Bangalore","year":"2014","journal-title":"Open Heart"},{"key":"10.1016\/j.jacc.2024.05.084_bib113","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1055\/s-0040-1709520","article-title":"Cilostazol for Chinese patients with aspirin intolerance after coronary drug-eluting stent implantation","volume":"120","author":"Dai","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2024.05.084_bib114","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/aps.2017.85","article-title":"The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis","volume":"39","author":"Xue","year":"2018","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.jacc.2024.05.084_bib115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1749-6632.2010.05801.x","article-title":"Effect of dipyridamole during acute stroke: exploring antithrombosis and neuroprotective benefits","volume":"1207","author":"d'Esterre","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jacc.2024.05.084_bib116","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jcin.2017.10.051","article-title":"A\u00a0multidisciplinary approach on the perioperative antithrombotic management of patients with coronary stents undergoing surgery: Surgery After Stenting 2","volume":"11","author":"Rossini","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.05.084_bib117","first-page":"41","article-title":"Early aspirin desensitization in unstable patients with acute coronary syndrome: short and long-term efficacy and safety","volume":"5","author":"Cordoba-Soriano","year":"2016","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.jacc.2024.05.084_bib118","first-page":"697","article-title":"Intracoronary bolus of glycoprotein IIb\/IIIa inhibitor as bridging or adjunctive strategy to oral P2Y12 inhibitor load in the modern setting of ST-elevation myocardial infarction","volume":"70","author":"Galli","year":"2022","journal-title":"Minerva Cardiol Angiol"},{"key":"10.1016\/j.jacc.2024.05.084_bib119","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.05.084_bib120","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.anai.2018.04.005","article-title":"Factors correlated with repeated aspirin dosing during aspirin desensitization","volume":"121","author":"Schuler","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacc.2024.05.084_bib121","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2021.01.003","article-title":"Severity grading system for acute allergic reactions: a multidisciplinary Delphi study","volume":"148","author":"Dribin","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jacc.2024.05.084_bib122","first-page":"160","article-title":"Aspirin challenge\/desensitisation before coronary stenting in subjects with history of hypersensitivity. A pragmatic approach","volume":"44","author":"Cortellini","year":"2012","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.jacc.2024.05.084_bib123","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/clc.22054","article-title":"Safety of aspirin desensitization in patients with reported aspirin allergy and cardiovascular disease","volume":"36","author":"McMullan","year":"2013","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacc.2024.05.084_bib124","first-page":"207","article-title":"Aspirin desensitisation for Chinese patients with coronary artery disease","volume":"19","author":"Lee","year":"2013","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.jacc.2024.05.084_bib125","first-page":"494","article-title":"Desensitization to acetylsalicylic acid in patients undergoing percutaneous coronary intervention. Experience in a tertiary center","volume":"67","author":"Diez-Villanueva","year":"2014","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.jacc.2024.05.084_bib126","first-page":"795","article-title":"Rapid desensitization to aspirin in patients with coronary artery disease: a single center experience","volume":"69","author":"Vega Hernandez","year":"2016","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.jacc.2024.05.084_bib127","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/1074248418823016","article-title":"Rapid aspirin desensitization is safe and feasible in patients with stable and unstable coronary artery disease: a single-center experience","volume":"24","author":"Jackson","year":"2019","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.jacc.2024.05.084_bib128","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.hjc.2021.07.003","article-title":"A\u00a0single center experience of rapid aspirin desensitization in acute coronary syndrome patients","volume":"64","author":"Vlachos","year":"2022","journal-title":"Hellenic J Cardiol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510972408313X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510972408313X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:37:59Z","timestamp":1761784679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073510972408313X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":128,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S073510972408313X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2024.05.084","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin Hypersensitivity in Patients With Atherosclerotic Cardiovascular Disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2024.05.084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}